迈科康生物 迈科康生物

CN

Maxvax founder and CEO Dr. Chen gave speech at GVIRF

HIT:442

On September 13th, 2023, the Global Health Vaccine Adjuvant Webinar, which was hosted by Global Vaccine and Immunization Research Forum (GVIRF), was successfully held. Maxvax was the only innovative vaccine company in China that was invited to attend the virtual seminar. On the meeting, Maxvax’s founder and CEO Dr. Dexiang Chen gave a presentation on Enhancing Public Health Capacity: Strengthening the Global Availability, Accessibility, and Affordability of Adjuvants and Formulations, and took part in the keynote discussion.

During the webinar, Dr. Chen introduced Maxvax’s novel adjuvant platform and its application and outlook in developing innovative vaccines. Dr. Chen highlighted the achievements of Maxvax in the GMP-compliant large-scale production of novel adjuvant raw materials and adjuvant formulations, showcasing research outcomes that have entered clinical trials. He also shared that the company is currently equipped with leading platform technologies and large-scale production capacity, and its novel adjuvants and delivery system can meet the demands for developing various innovative human vaccines. Maxvax has designed and synthesized over 20 types of novel immunomodulatory adjuvants belonging to six major categories: TLR3 (dsRNA class), TLR4 (monophosphoryl lipid A), TLR7/8, TLR9(oligonucleotides), saponins, and iNKT cell agonists. These adjuvants offer advantages such as controllable quality and stable supply compared with the adjuvant molecules derived from sustainable resources (plants and animals). Maxvax has initiated to establish drug master files for multiple adjuvants with both China and US regulatory entities and is open to collaborating with vaccine manufacturers and international organizations to deliver cost-effective adjuvant technologies and products. Together, this collaborative initiative aims to address emerging infectious diseases, promote the development of public health, and contribute to the well-being of human health.

About the Global Vaccine and Immunization Research Forum (GVIRF) and its webinar series

The Global Vaccine and Immunization Research Forum (GVIRF) and its webinar series, jointly organized by the National Institute of Allergy and Infectious Diseases (NIAID), the Bill & Melinda Gates Foundation (BMGF), and the World Health Organization (WHO), are held once every two years to contribute to the global achievement of the strategic goals of the Immunization Agenda 2030 (IA2030). The forum brings together leaders in the vaccine and immunization research community, from basic immunology to implementation research, with participants from low-income to high-income countries, to address research challenges and co-innovate.

This year’s webinar has been convened to promote the development of novel adjuvant and formulation technologies around the global demand, research and development of vaccine adjuvant, and to facilitate vaccine development to maximize vaccines’ protection for human beings.

About Maxvax

Maxvax is an international biopharmaceutical enterprise dedicated to the R&D, production and commercialization of innovative vaccines and new adjuvants. It has R&D centers and business teams in the Chinese cities of Chengdu, Shanghai and Hangzhou, as well as in Seattle, the United States. The industrialization base for its human vaccines is located in the Lin-gang Special Area of Shanghai. Maxvax focuses on the key and urgently required vaccines in clinical practice including preventive vaccines, therapeutic vaccines and tumor vaccines and has laid out diversified pipelines. At present, its first batch of two pipeline products has entered the clinical study stage.